Clinical trials: Parkinson's Disease, Lewy Body
Dementia With Lewy Bodies, REM Sleep Behavior Disorder
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia…
- Conditions
- Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
- Trial name
- NCT02708186
- Testing
- Nelotanserin
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Axovant Sciences Ltd.
Lewy Body Dementia, Parkinson Disease
Anti-Diabetic Medications to Fight PD and LBD
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
- Trial name
- NCT06263673
- Testing
- Sitagliptin, Dapagliflozin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Parkinson Disease (PD)
Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution
Parkinson's disease (PD) presents a complex challenge due to its progressive neurodegenerative nature, affecting various bodily systems.
- Trial name
- VaMPiRE (NCT06941012)
- Testing
- Blood draw for the laboratory assessment
- Where
- 4 sites in Greece, Italy and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Casa di Cura IGEA
Parkinson's Disease (PD), Parkinson's Disease
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
This clinical study is being conducted to learn more about a new imaging drug called [18F]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD).
- Conditions
- Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
- Trial name
- NCT07348250
- Testing
- [18F]MK-0947
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Parkinson's Disease
Vaccination Uptake (VAX) in PD
This is a study to see whether participation in the Edmond J. Safra Interdisciplinary Home Visit Program for Advanced Parkinson's (HVP) increases the rate of age-appropriate vaccinations in people with advanced Parkinson's…
- Trial name
- VAX-PD (NCT02874274)
- Testing
- Standard of Care, Home Visit Program (HVP)
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- NYU Langone Health
Parkinson's Disease, Healthy
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
The primary objective of the study is to evaluate the safety and tolerability of a range of single BIIB054 doses, administered as a single intravenous (IV) infusion, in healthy participants and participants with early Parkinson's…
- Trial name
- NCT02459886
- Testing
- BIIB054
- Where
- 9 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Biogen
Parkinson Disease, PD
Genetic Characterization of Parkinson's Disease
This study will explore the risks and causes of Parkinson's disease, a chronic progressive nervous system disorder. Patients typically have tremors, muscle weakness and a shuffling gait.
- Conditions
- Parkinson Disease, PD, Movement Disorder, Healthy Volunteer
- Trial name
- NCT00105131
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson Disease, REM Sleep Behavior Disorder
Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder
The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia…
- Conditions
- Parkinson Disease, REM Sleep Behavior Disorder, Dementia, Lewy Body
- Trial name
- NUK-RBD (NCT06629207)
- Testing
- PET/CT with 18-FDG, SPECT : 123 I-FP-CIT (DATSCAN), MRI
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Alzheimer Dementia, Dementia, Vascular
Tailored Music Therapy for Dementia
This study evaluates the effect and process of individualized music therapy for home-dwelling persons with mild to moderate dementia. The music therapy is administered individually and includes a close caregiver.
- Conditions
- Alzheimer Dementia, Dementia, Vascular, Dementia, Lewy Body, Dementia Parkinson's Disease
- Trial name
- NCT03011723
- Testing
- Resource oriented music therapy
- Where
- Norway
- Volunteers
- 11 people
- Sponsor
- University of Bergen
Parkinson's Hallucinations, Dementia With Lewy Bodies
Trial of Ondansetron as a Parkinson's HAllucinations Treatment
TOPHAT (Trial of Ondansetron as a Parkinson's HAllucinations Treatment) is a double blind, individually randomized, placebo-controlled, parallel group, flexible dose trial of ondansetron (8-24mg/day) as a treatment for…
- Trial name
- TOP HAT (NCT04167813)
- Where
- 23 sites in United Kingdom
- Volunteers
- 168 people
- Sponsor
- University College, London
Alpha-Synucleinopathy, Parkinson's Disease
Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain
The overall goal of this protocol is to evaluate [18F]MNI-1216 (also known as [18F]ACI-12589) as an α-synuclein targeted radiopharmaceutical in 3 parts as follows: Part 1: first in human (FiH) imaging Optional Part 2: expansion…
- Conditions
- Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
- Trial name
- NCT06445465
- Testing
- [18F]MNI-1216
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro
Parkinson Disease
GALIG Gene Expression in Parkinson's Disease
Parkinson's disease (PD) is the most frequent neurodegenerative disorder after Alzheimer's disease. It is characterized by motor symptoms (rigidity, tremor, slowness of movements), and non-motor symptoms (neuropsychological…
- Trial name
- GALIGPARK (NCT02923297)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Parkinson Disease
FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)
The overall objective of this study is to compare the performance of available oligomeric and phosphorylated a-synuclein assay in cerebrospinal fluid and blood.
- Trial name
- SAVE001 (NCT03170063)
- Testing
- Procedure/Surgery: Biofluid samplings
- Where
- 5 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
Parkinson's Disease
Systemic Synuclein Sampling Study (S4)
The purpose of this study is to measure alpha-synuclein in peripheral body tissues and fluids in Parkinson's disease (PD). This may help in developing better treatments for PD patients in the future.
- Trial name
- S4 (NCT02572713)
- Testing
- Biofluid samplings, Tissue samplings, DaTSCAN™
- Where
- 6 sites in United States, Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
Parkinson Disease, MSA - Multiple System Atrophy
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Lewy Body Dementia (LBD), Neurodegenerative Disease
- Trial name
- EXTRAORDINARY (NCT06846658)
- Where
- 3 sites in Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Parkinson Disease, Dementia, Lewy Body
Music Therapy to Prevent Hospital-acquired Delirium in Parkinson's Disease and Dementia With Lewy Bodies
The goal of this clinical trial is to test whether a music therapy intervention (MT) prevents hospital-acquired delirium (HaD) in patients with Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB).
- Conditions
- Parkinson Disease, Dementia, Lewy Body, Delirium
- Trial name
- NCT06063161
- Testing
- Music therapy intervention, Standard Care (in control arm)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Massachusetts, Worcester
Parkinson Disease, Cognitive Dysfunction
Predictors of Parkinson's Disease Progression
it is a prospective longitudinal observational study, aiming to to identify clinical, and biochemical baseline predictors of motor and non-motor PD progression in sample of Egyptian patients.
- Conditions
- Parkinson Disease, Cognitive Dysfunction, Biomarkers
- Trial name
- PDPROG-EGY (NCT04062279)
- Testing
- serum alpha synuclein autoantibodies, motor and non motor scales
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Parkinson's Disease
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
The primary objective of the study is to evaluate the clinical efficacy of BIIB054 via dose response using the change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score.
- Trial name
- SPARK (NCT03318523)
- Testing
- BIIB054
- Where
- 75 sites in United States, Austria and 7 more
- Volunteers
- 357 people
- Sponsor
- Biogen
REM Behavior Disorder, Parkinsonism
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
Parkinson's disease (PD) is the second most common neurodegenerative disorder of the elderly that affects a million patients in US. Sleep dysfunction impacts up to 90% of PD patients.
- Trial name
- NCT00745030
- Testing
- Rozerem
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.